Dorsey Wright & Associates Buys New Stake in Grifols, S.A. $GRFS

Dorsey Wright & Associates purchased a new position in Grifols, S.A. (NASDAQ:GRFS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 145,236 shares of the biotechnology company’s stock, valued at approximately $1,447,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Montreal Can grew its position in shares of Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock valued at $30,017,000 after purchasing an additional 2,922,540 shares in the last quarter. Brandes Investment Partners LP increased its holdings in shares of Grifols by 8.9% in the second quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock worth $253,441,000 after purchasing an additional 2,294,113 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Grifols by 383.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after buying an additional 2,221,633 shares in the last quarter. Norges Bank purchased a new stake in shares of Grifols in the second quarter worth about $17,538,000. Finally, Capital World Investors boosted its stake in Grifols by 5.9% during the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock valued at $228,344,000 after buying an additional 1,273,391 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. JPMorgan Chase & Co. lowered their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research report on Monday, December 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Grifols in a report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Grifols Trading Down 0.4%

GRFS opened at $8.02 on Wednesday. The stock has a 50-day moving average of $9.02 and a 200 day moving average of $9.19. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. Grifols, S.A. has a 12 month low of $6.19 and a 12 month high of $11.14.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.